NTRK1 and neuroblastoma: Crizotinib/PF-02341066 is a small molecule inhibitor targeting ALK and other receptor tyrosine kinases, MET and ROS1, that decreased proliferation in neuroblastoma cell lines with abnormal ALK, particularly those with the R1275Q mutation [130].